Clinical Trial Update: MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003) [Phase 2]

View source ↗

Summary

Phase 2 trial of MK-3795 (PT2385) for Von Hippel-Lindau–associated clear cell renal cell carcinoma has completed with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Von Hippel-lindau Disease

Drugs mentioned

• MK-3795 (PT2385)

Snippet

Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: VHL Gene Mutation, VHL | Phase 2 | Status: COMPLETED | Results posted: 2024-09-24